Natera Inc

2026. okt. 26. 19:56 UTC

Natera Inc presented findings at the American Society of Nephrology, revealing a median 5.3-year delay in chronic kidney disease diagnosis and care access issues.

2026. okt. 23. 20:07 UTC

Roth initiates coverage on Natera Inc with a Buy rating and sets a price target of $475, reflecting confidence in the company's growth potential.

2026. okt. 22. 20:03 UTC

Natera Inc shares are declining, having significantly pulled back from earlier gains and reaching a notable low around midday, amid unusually high market volume.

2026. okt. 20. 19:36 UTC

Natera Inc is trading higher, rebounding from an earlier dip to reach a mid-afternoon peak, currently above its 20-day moving average.

2026. okt. 19. 22:51 UTC

Natera Inc shares traded modestly lower during after-market hours on Monday, remaining below their 20-day moving average amid broader market weakness.

2026. okt. 17. 00:01 UTC

Natera Inc shares are trading modestly lower in after-market hours, remaining below their 20-day moving average amid broader market weakness.

2026. okt. 16. 23:06 UTC

Natera Inc is trading slightly higher in after-market hours, fluctuating between nearly 1.71% below and 0.31% above Friday's close.

2026. okt. 15. 20:07 UTC

Natera's Signatera test recognized in TIME's Best Inventions of 2026, underscoring its impact on cancer care and supported by over 200 peer-reviewed publications.

2026. okt. 14. 22:21 UTC

Natera Inc shares are trading modestly lower in after-market hours, following a significant decline in major indices amid rising investor anxiety over interest rate decisions.

2026. okt. 13. 20:08 UTC

Natera Inc. partners with TransCode Therapeutics to boost patient enrollment in a colorectal cancer trial, while TD Cowen and Morgan Stanley raise price targets to $480 and $435.

2026. okt. 12. 20:06 UTC

Natera Inc shares are declining, pulling back from an earlier high, despite being nominated for the 2026 Future Investors Awards as a top healthcare company.

2026. okt. 9. 20:07 UTC

Natera Inc.'s multi-cancer early detection assay received Breakthrough Device designation from the FDA, aimed at improving early cancer diagnosis and treatment options.

2026. okt. 8. 20:07 UTC

Baird analyst Catherine Ramsey Schulte raised Natera Inc's price target to $458.00 from $376.00 while maintaining an Outperform rating.

2026. okt. 7. 20:00 UTC

Natera Inc. shares fell despite the enrollment of patients in a study for advanced melanoma and Barclays raising its price target to $475 from $340.

2026. okt. 6. 20:00 UTC

Natera Inc shares fell amid broader biotechnology sector weakness, despite positive data on its Signatera product and Citigroup raising its price target to $480.

2026. okt. 5. 23:05 UTC

Citi raised its price target on Natera Inc to $480 from $365, maintaining a Buy rating amid growth in its Signatera product and health segments.

2026. okt. 2. 20:07 UTC

Natera Inc shares are higher amid a broadly advancing market, reflecting positive momentum as labor statistics influence expectations for future interest rates.

2026. okt. 1. 20:07 UTC

Natera Inc shares are declining, reversing earlier gains despite remaining above the 20-day moving average and near the upper end of the one-month range.

2026. szept. 30. 23:00 UTC

Natera Inc declined in after-market trading, settling below Wednesday's close after retreating from an early high, despite remaining higher over the past month.

2026. szept. 29. 19:15 UTC

Natera Inc shares are modestly higher as social media buzz highlights positive cash flows and a potential cancer screening test amid market volatility.

2026. szept. 28. 20:07 UTC

Natera's shares fell amid a broader market decline, despite RBC Capital raising its price target to $460 and maintaining an Outperform rating.

2026. szept. 25. 19:46 UTC

RBC Capital raised its price target on Natera Inc to $460, maintaining an Outperform rating, as shares trade modestly higher amid strong market position.

2026. szept. 24. 23:01 UTC

Natera Inc is trading modestly lower in after-market hours, having retraced from an early gain and reflecting a cumulative decline since Thursday's close.

2026. szept. 22. 20:02 UTC

Natera Inc's Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, driving the stock sharply higher.

2026. szept. 21. 22:11 UTC

Natera Inc is trading modestly higher in after-market hours, remaining well above its 20-day moving average following a peak earlier in the session.

2026. szept. 18. 22:31 UTC

Natera Inc declined in after-market trading, moving lower since Friday's close, despite previously trading above its 20-day moving average.

2026. szept. 17. 23:06 UTC

Natera Inc's shares traded flat in after-market hours, remaining 10.18% above the 20-day moving average amid positive economic indicators.

2026. szept. 16. 19:07 UTC

Natera Inc shares fell modestly lower, reaching a notable low today, though remaining above their 20-day moving average.

2026. szept. 15. 23:01 UTC

Natera Inc shares are higher in after-market hours following Tuesday's close, continuing a trend of four consecutive sessions that also closed higher.

2026. szept. 14. 19:26 UTC

Natera Inc is gaining momentum as it breaks above September's value area. UBS raised its price target while maintaining a "buy" rating.